In a breakthrough that could change the outlook for one of the deadliest cancers, researchers at the nonprofit City of Hope in California have unveiled an experimental blood test called Panxeon. The test, which combines three biomarkers and artificial‑intelligence analysis, has shown the ability to detect early‑stage pancreatic cancer and high‑grade dysplasia—an advanced precancerous condition—well before symptoms appear.
Why early detection matters
Pancreatic cancer has the lowest five‑year survival rate of any major cancer, with only about one in seven patients living five years after diagnosis. Roughly 90% of cases are discovered only after the tumor has spread, limiting treatment options and reducing the chance of cure.
How the Panxeon test works
Panxeon measures three distinct signals in a single blood sample: circulating microRNAs, exosomal microRNAs, and the protein marker CA19‑9. An AI algorithm integrates these measurements into a risk score that estimates a patient’s likelihood of having pancreatic cancer.
Study results
In a study published in Nature Medicine, more than 1,700 participants from the United States, Europe, and Asia were tested. The test correctly identified stage 1 and 2 pancreatic cancer 87% of the time. False‑positive rates were low—about 3% among low‑risk individuals and 16% among high‑risk groups. The assay also detected high‑grade dysplasia in over 64% of cases, a condition often considered “stage 0” pancreatic cancer.
Potential impact on patient care
Lead author Ajay Goel, a senior researcher at City of Hope, emphasized that the test is not intended to replace imaging or other diagnostic tools. Instead, it could serve as a screening step to identify high‑risk patients—those with a family history of pancreatic cancer, inherited genetic risk, pancreatic cysts, or chronic pancreatitis—who would then undergo further evaluation.
“Most biomarkers tell you only one part of the story,” Goel said. “Combining multiple biological signals gives us a clearer picture of what may be happening in the pancreas.” He added that earlier detection dramatically improves the chances that meaningful intervention remains possible.
What comes next
While the results are promising, Panxeon remains investigational. Larger clinical trials are planned to confirm its performance across broader populations and to assess how it can be integrated into routine screening protocols for high‑risk groups. If successful, the test could reduce reliance on invasive procedures and costly imaging, easing the diagnostic burden on patients and the healthcare system.
For families with a history of pancreatic cancer or those managing chronic pancreatic conditions, the development offers a hopeful new tool in the fight against a disease that has long been difficult to catch early.
Original reporting: KTBS 3 (Shreveport) — read the source article.
